First-line everolimus plus exemestane prolonged PFS in advanced breast cancer Healio The addition of the mTOR inhibitor everolimus to first-line exemestane therapy extended PFS compared with exemestane alone in patients with hormone receptor-positive advanced breast cancer, according to study results presented at the Breast Cancer ... |
